Sars-Cov Spike Clone 3014

Description: SARS-CoV-2 - Spike ELISA IgG

Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

Description: Mouse Anti Bovine Coronavirus Spike

Description: Mouse Anti Porcine Coronavirus Spike

Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective Assay kit detecting the levels of anti-SARS-CoV-2 in human serum can facilitate research on characterization of antibodies produced in response to SARS-CoV-2 infection.

Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective Assay kit detecting the levels of anti-SARS-CoV-2 in human serum can facilitate research on characterization of antibodies produced in response to SARS-CoV-2 infection.

Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective Assay kit detecting the levels of anti-SARS-CoV-2 in human serum can facilitate research on characterization of antibodies produced in response to SARS-CoV-2 infection.

Description: This human monoclonal antibody recognizes SARS-CoV-2 full-length spike proteins in the native trimeric conformation. This antibody cross-reacts with the wildtype (BPS Bioscience #100728) as well as the Alpha B.1.1.7 (BPS Bioscience #510334), Beta B.1.351 (BPS Bioscience #510333), Beta B.1.351Δ242-244 (BPS Bioscience #101091), Gamma P.1 (BPS Bioscience #100989), Delta B.1.617.2 (BPS Bioscience #101147) and Delta Plus B.1.617.2.1 (BPS Bioscience #101165) variant spike trimers [Table of variants]. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. ACE2 is known to mediate COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike Trimer: ACE2 Inhibitor Screening Kits (available for purchase).

Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Description: SARS-CoV-2 (COVID-19) spike antibody (Spike (S1), Polyclonal)

Description: SARS-CoV-2 (COVID-19) spike antibody (Spike (S1), Polyclonal)

Description: SARS-CoV-2 Spike Antibody, Recombinant Human

Description: SARS-CoV-2 Spike Antibody, Recombinant Human

Description: SARS-CoV-2 Spike Antibody, Recombinant Human

Description: SARS-CoV-2 Spike Antibody, Recombinant Human

Description: Anti-SARS-CoV-2 Spike Protein Monoclonal antibody

Description: Anti-SARS-CoV-2 Spike Protein Monoclonal antibody

Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

Description: Recombinant anti SARS-CoV-2 (2019-nCov) Spike Glycoprotein S1 monoclonal blocking antibody (clone Covi-1) (100 ug)

Description: Recombinant anti SARS-CoV-2 (2019-nCov) Spike Glycoprotein S1 monoclonal blocking antibody (clone Covi-2) (100 ug)